Pliant Therapeutics, Inc. (PLRX)

USD 14.0

(-2.57%)

Market Cap (In USD)

851.95 Million

Revenue (In USD)

1.58 Million

Net Income (In USD)

-161.33 Million

Avg. Volume

502.32 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
10.22-19.62
PE
-
EPS
-
Beta Value
1.087
ISIN
US7291391057
CUSIP
729139105
CIK
1746473
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Bernard Coulie M.B.A., M.D., Ph.D.
Employee Count
-
Website
https://pliantrx.com
Ipo Date
2020-06-03
Details
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.